Establishment Labs reported a strong Q2 2026 with 31.7% revenue growth and gross margins expanding to 70.6%, driven mainly by U.S. sales which accounted for 89% of growth. The company's FDA-approved Preservé product offers over twice the revenue per breast augmentation procedure compared to traditional implants, positioning it for higher-margin growth. However, the long-term success depends on repeat use and maintaining strong economics. Investors should watch for risks related to Preservé adoption, safety outcomes, and cash flow conversion, especially given the current valuation at 8.91x forward EV/sales.
ILC Critical Minerals Ltd. successfully passed all resolutions at its September 8, 2026 annual general meeting, with over 99% shareholder approval. The company re-elected its board and reaffirmed its focus on lithium, rubidium, and copper projects in...
WELL Health Technologies announced Evelyn Sutherland will become CFO on September 21, 2026, bringing over 20 years of financial leadership experience. She has served on WELL's subsidiary board and has expertise in capital markets and M&A. The current...
Dryden Gold Corp. announced initial results from its 2026 exploration program at the Hyndman Property, revealing grab samples with gold grades up to 31.20 g/t. The program includes extensive mapping, Heavy Mineral Concentrate sampling, and till subst...
IDEAYA Biosciences and Servier have started dosing the first patient in OptimUM-11, a global Phase 3 trial testing darovasertib combined with crizotinib as adjuvant therapy for primary uveal melanoma patients at high risk of metastasis after local tr...
The Cigna Group, a global health company, announced it will host its Investor Day on September 30, 2026, starting at 8:30 a.m. ET. The event will feature detailed presentations on the company's corporate strategy and financial goals. Investors can wa...
